Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis

References

• GOLD (Global Initiative for Chronic Obstructive Lung Disease)Global strategy for the diagnosis, management, and prevention of COPD2010 http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed February 1, 2010.
   Google Scholar
• KatzPMPegoraroVL’utilizzo dei corticosteroidi nei pazienti con la broncopneumopatia cronica ostruttiva: aspetti epidemiologici ed economiciFarmeconomia e percorsi terapeutici2009104139148
   Google Scholar
• European Medicines AgencyOnbrez Breezhaler indacaterol. Doc.Ref.: EMA/625202/20092010 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001114/WC500053733.pdf. Accessed February 1, 2010.
   Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• FeldmanGSilerTPrasadNEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med201010111920051135
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J20113727327920693243
   PubMed Web of Science ®Google Scholar
• CaldwellDMAdesAEHigginsJPSimultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ2005331752189790016223826
   PubMed Web of Science ®Google Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• JansenJCrawfordBBergmanGStamWBayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisonsValue Health2008115964966
   Web of Science ®Google Scholar
• DempsterAPThe direct use of likelihood for significance testingStat Comput19977247252
   Web of Science ®Google Scholar
• CooperNJSuttonAJMorrisDAdesAEWeltonNJAddressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillationStat Med2009281861188119399825
   PubMed Web of Science ®Google Scholar
• LunnDJThomasABestNSpiegelhalterDWinBUGS – a Bayesian modelling framework: concepts, structure, and extensibilityStat Comput200010325337
   Web of Science ®Google Scholar
• BarnesNQiuYPavordIParkerDDavisPZhuJAntiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung diseaseAm J Respir Crit Care Med2006173773674316424444
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJrCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPAndersonJCelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• HananiaNDarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 mug)/salmeterol (50 mug) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• MahlerDWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• ZhengJYangLWuYThe efficacy and safety of combination salmeterol (50 mug)/fluticasone propionate (500 mug) inhalation twice daily via accuhaler in Chinese patients with COPDChest200713261756176317951625
   PubMed Web of Science ®Google Scholar
• IqbalALeanHLawrenceDHigginsM Full Clinical Study Report for study number CQAB149B2335S: A 26-week treatment, multicenter, randomized, doubleblind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 and 600 μg o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 μg b.i.d) and open label tiotropium (18 μg o.d.) as active Controls. Data on file: 2008.
   Google Scholar
• LuthraAKramerBSwalesJHenleyMLassenC Full Clinical Study Report for study number CQAB149B2336: A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg b.i.d.) as an active control. Data on file: 2009.
   Google Scholar
• HosoeMOkinoNMaruyamaY Full Clinical Study Report for study number CQAB149B1302: A 12-week treatment, multi-center, randomized, double blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of Indacaterol (150 and 300 ìg o.d.) in patients with chronic obstructive pulmonary disease (COPD). Data on file: 2010.
   Google Scholar
• FirthRHenleyMKramerBLassenCYangWOwenR Full Clinical Study Report for study number QAB149B2333: A phase III, 26-week multi-center randomized double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (150 and 300 ìg o.d.) in patients with chronic obstructive pulmonary disease. Data on file: 2010.
   Google Scholar
• JackDBleasdalePBerhaneIHigginsM Full Clinical Study Report for study number CQAB149B2334: A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 and 600 μg o.d.) in patients with chronic obstructive pulmonary disease, using formoterol (12 μg b.i.d.) as an active control. Data on file: 2008.
   Google Scholar
• PrasadNPiggottSHigginsMYuT Full Clinical Study Report for study number CQAB149B2346: A 12-week treatment, multi-center, randomized, doubleblind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease. Data on file: 2008.
   Google Scholar
• JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• WitekTJJrMahlerDAMinimal important difference of the transition dyspnoea index in a multinational clinical trialEur Respir J200321226727212608440
   PubMed Web of Science ®Google Scholar